13M164: Abstracts: RA – Treatments II: RA Treatment Safety (1675–1680)

Presenting Author(s)

• AA

  Abhishek Abhishek, MD, PhD, MBBS, FRCP

  University of Nottingham
  Nottingham, United Kingdom

  Disclosure information not submitted.
• 

  Rieke Alten, MD, PhD

  SCHLOSSPARK KLINIK, University Medicine Berlin
  Berlin, Germany

  Disclosure information not submitted.
• PD

  Paula David, MD (she/her/hers)

  Medical doctor graduated in Rio de Janeiro State University, Internal Medicine resident in Sheba Medical Center Tel Hashomer, Experimental Rheumatology Fellow in University of Leeds, UK
  Ramat Gan, Israel

  Disclosure information not submitted.
• XS

  Xavier Sendaydiego, MD

  University of Washington
  Seattle, WA, United States

  Disclosure information not submitted.
• MS

  Maria Suarez-Almazor, MD, PhD (she/her/hers)

  MD Anderson Cancer Center
  Houston, TX, United States

  Disclosure information not submitted.
• KY

  Kazuhiro Yokota, MD, PhD

  Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University
  Iruma-gun, Japan

  Disclosure information not submitted.

Abstract oral session.

Non-CME

Presentations:

• 4:00 PM - 4:10 PM PT

  Survival in Patients with Rheumatoid Arthritis and Early Breast Cancer Treated with Tumor Necrosis Factor Inhibitors
  

  Presenting Author: Maria Suarez-Almazor, MD, PhD (she/her/hers) – MD Anderson Cancer Center
• 4:10 PM - 4:15 PM PT

  Q&A
  
• 4:15 PM - 4:25 PM PT

  Tofacitinib Accelerates in Vitro Clot Formation and Delays Clot Lysis in Rheumatoid Arthritis Blood by Enhancement of Macrophage TLR4 Mediated Cytokine Responses- a New Angle on Thrombosis with JAKi in Rheumatology
  

  Presenting Author: Paula David, MD (she/her/hers) – Medical doctor graduated in Rio de Janeiro State University, Internal Medicine resident in Sheba Medical Center Tel Hashomer, Experimental Rheumatology Fellow in University of Leeds, UK
• 4:25 PM - 4:30 PM PT

  Q&A
  
• 4:30 PM - 4:40 PM PT

  Two-week Break in Methotrexate Treatment and COVID-19 Vaccine Response. Results of the Vaccine Response on off Methotrexate (VROOM) Study, an Open Label, Prospective, Two-arm Parallel-group, Multi-center, Superiority, Randomized Controlled Trial
  

  Presenting Author: Abhishek Abhishek, MD, PhD, MBBS, FRCP – University of Nottingham
• 4:40 PM - 4:45 PM PT

  Q&A
  
• 4:45 PM - 4:55 PM PT

  Comparative Safety of Biologic and Targeted Synthetic Disease Modifying Anti-Rheumatic Drugs for Cancer in Rheumatoid Arthritis
  

  Presenting Author: Xavier Sendaydiego, MD – University of Washington
• 4:55 PM - 5:00 PM PT

  Q&A
  
• 5:00 PM - 5:10 PM PT

  Effects of Janus Kinase Inhibitor on TNF-a and IL-6-Induced Osteoclasts and RANKL-Induced Osteoclasts in Peripheral Blood Monocytes from Patients with Rheumatoid Arthritis
  

  Presenting Author: Kazuhiro Yokota, MD, PhD – Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University
• 5:10 PM - 5:15 PM PT

  Q&A
  
• 5:15 PM - 5:25 PM PT

  What Trade-offs Are Acceptable to Rheumatoid Arthritis Patients During Treatment Selection?
  

  Presenting Author: Rieke Alten, MD, PhD – SCHLOSSPARK KLINIK, University Medicine Berlin
• 5:25 PM - 5:30 PM PT

  Q&A